{"entity": "researcher", "timestamp": "2026-08-28T00:11:23.642Z", "family": "Gudoityte", "given": "Greta", "initials": "G", "orcid": "0000-0003-1963-7856", "affiliations": ["Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, 171 21 Stockholm, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/4b2d8cfbdc804c2c996acef7d6cf4f26.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/4b2d8cfbdc804c2c996acef7d6cf4f26"}}, "publications": [{"entity": "publication", "iuid": "ed04fa15d77e4480b0c581a635e4c7e7", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/ed04fa15d77e4480b0c581a635e4c7e7.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/ed04fa15d77e4480b0c581a635e4c7e7"}}, "title": "Ex Vivo Drug Sensitivity of Pleural Effusion-Derived Cells from Lung Cancer and Pleural Mesothelioma Patients Is Linked to Clinical Response.", "authors": [{"family": "Hutyra-Gram \u00d6tv\u00f6s", "given": "Rita", "initials": "R"}, {"family": "Krynska", "given": "Hanna", "initials": "H", "orcid": "0000-0002-3759-3503", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d80060cb378147db9edbb5b8e2b18c06.json"}}, {"family": "Gudoityte", "given": "Greta", "initials": "G", "orcid": "0000-0003-1963-7856", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4b2d8cfbdc804c2c996acef7d6cf4f26.json"}}, {"family": "Skribek", "given": "Marcus", "initials": "M", "orcid": "0000-0001-8692-6426", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/94e730abe32349699438862190f45b69.json"}}, {"family": "Oniscu", "given": "Anca", "initials": "A"}, {"family": "Berkovska", "given": "Olena", "initials": "O", "orcid": "0000-0002-8811-0591", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/887be29288744e6c860e1e00a2501dce.json"}}, {"family": "Strau\u00df", "given": "Katharina", "initials": "K"}, {"family": "Zipprick", "given": "Jenny", "initials": "J", "orcid": "0009-0001-1880-3261", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0bcef0390cfe416d8d2b3df728ae372f.json"}}, {"family": "Tamborero", "given": "David", "initials": "D"}, {"family": "Alexeyenko", "given": "Andrey", "initials": "A", "orcid": "0000-0001-8812-6481", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8078f1505d9747e1ac76cf2f6d4ee606.json"}}, {"family": "Gad", "given": "Annica Karin Britt", "initials": "AKB", "orcid": "0000-0002-1098-9129", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0d66fa4c2ba64ddbbcc410b65234c892.json"}}, {"family": "Seashore-Ludlow", "given": "Brinton", "initials": "B", "orcid": "0000-0001-8658-5967", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8a8ea4c3fdb14de1b651d0367b0a70a4.json"}}, {"family": "Dobra", "given": "Katalin", "initials": "K", "orcid": "0000-0002-0207-6733", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f8218ca8a6a5451ca92a613260fb47dd.json"}}], "type": "journal article", "published": "2025-07-16", "journal": {"title": "Cancers (Basel)", "issn": "2072-6694", "volume": "17", "issue": "14", "issn-l": "2072-6694"}, "abstract": "Tumors of the pleura, such as metastatic lung cancer and mesothelioma, are amongst the most lethal and therapy-resistant tumors. The first manifestation of the disease is often pleural effusion, the first available material for diagnosis. The five-year survival rate is exceptionally low, around 10-20%, and only a small proportion of patients harbor mutations that allow targeted treatments. Almost all patients develop resistance to treatment, which is often palliative. There is therefore an urgent need to refine the selection of drugs and patients for personalized treatment.\n\nWe isolated and cultured cells from pleural effusions in 3D cell aggregates and compared their drug sensitivity ex vivo to the clinical response to the same chemotherapeutic agents, combined with targeted sequencing and network analysis.\n\nThe ex vivo drug response showed a positive correlation with the treatment response and survival of patients in the clinic, with a stronger link to overall survival than to progression-free survival. Cryopreserved cells showed a similar response to freshly collected cells from the clinic.\n\nThe findings advance the field of ex vivo screening and present an opportunity to combine strategies for functional precision medicine with comprehensive characterization of disease for improved treatment and future management of lung cancer.", "doi": "10.3390/cancers17142363", "pmid": "40723246", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12293284"}, {"db": "pii", "key": "cancers17142363"}], "notes": [], "created": "2026-08-21T13:02:00.936Z", "modified": "2026-08-21T13:02:01.227Z"}, {"entity": "publication", "iuid": "f9f23e6d98a141c28ab9d7cb97cfcf4c", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/f9f23e6d98a141c28ab9d7cb97cfcf4c.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/f9f23e6d98a141c28ab9d7cb97cfcf4c"}}, "title": "PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.", "authors": [{"family": "Ninou", "given": "Anna Huguet", "initials": "AH"}, {"family": "Lehto", "given": "Jemina", "initials": "J", "orcid": "0000-0002-2827-5749", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0e82ec8c7fdf4e7587085b3ab88db07f.json"}}, {"family": "Chioureas", "given": "Dimitrios", "initials": "D"}, {"family": "Stigsdotter", "given": "Hannah", "initials": "H"}, {"family": "Schelzig", "given": "Korbinian", "initials": "K"}, {"family": "\u00c5kerlund", "given": "Emma", "initials": "E"}, {"family": "Gudoityte", "given": "Greta", "initials": "G", "orcid": "0000-0003-1963-7856", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4b2d8cfbdc804c2c996acef7d6cf4f26.json"}}, {"family": "Joneborg", "given": "Ulrika", "initials": "U"}, {"family": "Carlson", "given": "Joseph", "initials": "J"}, {"family": "Jonkers", "given": "Jos", "initials": "J", "orcid": "0000-0002-9264-9792", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/76160d55579a447781962cb659a91933.json"}}, {"family": "Seashore-Ludlow", "given": "Brinton", "initials": "B"}, {"family": "Gustafsson", "given": "Nina Marie Susanne", "initials": "NMS", "orcid": "0000-0001-6401-0548", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cc62b4a3a4e84fa0b8a9f10d88710ccb.json"}}], "type": "journal article", "published": "2021-07-18", "journal": {"title": "Cancers (Basel)", "issn": "2072-6694", "volume": "13", "issue": "14", "issn-l": "2072-6694"}, "abstract": "Replicative repair of interstrand crosslinks (ICL) generated by platinum chemotherapeutics is orchestrated by the Fanconi anemia (FA) repair pathway to ensure resolution of stalled replication forks and the maintenance of genomic integrity. Here, we identify novel regulation of FA repair by the cancer-associated glycolytic enzyme PFKFB3 that has functional consequences for replication-associated ICL repair and cancer cell survival. Inhibition of PFKFB3 displays a cancer-specific synergy with platinum compounds in blocking cell viability and restores sensitivity in treatment-resistant models. Notably, the synergies are associated with DNA-damage-induced chromatin association of PFKFB3 upon cancer transformation, which further increases upon platinum resistance. FA pathway activation triggers the PFKFB3 assembly into nuclear foci in an ATR- and FANCM-dependent manner. Blocking PFKFB3 activity disrupts the assembly of key FA repair factors and consequently prevents fork restart. This results in an incapacity to replicate cells to progress through S-phase, an accumulation of DNA damage in replicating cells, and fork collapse. We further validate PFKFB3-dependent regulation of FA repair in ex vivo cultures from cancer patients. Collectively, targeting PFKFB3 opens up therapeutic possibilities to improve the efficacy of ICL-inducing cancer treatments.", "doi": "10.3390/cancers13143604", "pmid": "34298817", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8306909"}, {"db": "pii", "key": "cancers13143604"}], "notes": [], "created": "2026-08-20T13:39:32.625Z", "modified": "2026-08-20T13:39:32.824Z"}]}